researcher comment: amg 510 for kras mutation-positive nsclc | ramaswamy govindan
Published 4 years ago • 439 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
3:55
govindan discusses the phase i results of amg 510 evaluated in nsclc
-
3:41
amg 510 kras inhibitor trial results – ‘a good start’ | colin lindsay
-
4:44
practical considerations for amg 510 in kras-mutant nsclc
-
4:09
kras g12c inhibition in advanced nsclc: amg 510
-
7:23
targeted therapy for kras-mutant nsclc
-
12:26
【陈巍学基因】视频36：kras与肿瘤靶向治疗
-
10:42
gene set analysis of gwas with magma in omicsbox
-
18:13
microscopy: disassembling an asi ramm (nico stuurman)
-
7:51
kras g12c inhibition in advanced nsclc: amg 510
-
1:08
dr. fakih on the safety profile of amg 510 in kras g12c-mutated crc
-
3:46
david s. hong, md, regarding the phase i clinical trial investigating sotorasib (amg 510)
-
43:27
ramaswamy govindan, m.d., kras targeted therapies, kras kickers connect, september 25, 2021
-
2:49
targeted therapy for kras p.g12c nsclc
-
1:05
marwan fakih, md, considers implications from the amg 510 trial
-
6:53
amg 510, a novel krasg12c inhibitor, evaluated in nsclc -- r. govindan
-
4:06
amg 510 for targeting kras g12c mutant solid tumours
-
1:37
expert discusses kras g12c inhibitors for patients with nsclc
-
1:08
what is a kras mutation in non-small cell lung cancer (nsclc)?
-
7:00
kras-mutant nsclc
-
3:26
amg 510: a novel molecule targeting kras g12c mutatant solid tumours
-
4:20
sotorasib,fda,lumakras amgen 510,non-small cell lung cancer